Variability in Response to Antihypertensive Drugs

Barry J Materson

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Heterogeneity of treatment effects (HTE) is a measure of the variations in individual treatment response to the same agent across a population. Hypertension affords an appropriate model for investigators of HTE. Use of blood pressure measurement guidelines and consistent techniques help to reduce the potential variability associated with clinician measurements. Patient characteristics such as age and race/ethnicity can affect blood pressure, including patient response and adverse events observed with antihypertensive medication. Through pharmacogenetic advances, potential underlying causes for such variation are emerging. The growing number of clinical examples of mutations that affect antihypertensive response includes multiple polymorphisms within the components of the renin-angiotensin-aldosterone system. The most prominent examples of these polymorphisms exist in the genes coding for angiotensinogen, angiotensin-converting enzyme, and the angiotensin II type 1 receptor. An understanding of the components of blood pressure variability and sources of HTE in antihypertensive therapy is important for analyzing published reports on this topic. It is also helpful when designing treatment protocols for individual patients with hypertension and in assessing their response to therapy.

Original languageEnglish
JournalAmerican Journal of Medicine
Volume120
Issue number4 SUPPL.
DOIs
StatePublished - Apr 1 2007

Fingerprint

Antihypertensive Agents
Blood Pressure
Therapeutics
Hypertension
Angiotensinogen
Angiotensin Type 1 Receptor
Pharmacogenetics
Peptidyl-Dipeptidase A
Renin-Angiotensin System
Clinical Protocols
Research Personnel
Guidelines
Mutation
Population
Genes

Keywords

  • Antihypertensive drugs
  • Biologic characteristics
  • Drug resistance
  • Heterogeneity
  • Population characteristics
  • Populations at risk

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Variability in Response to Antihypertensive Drugs. / Materson, Barry J.

In: American Journal of Medicine, Vol. 120, No. 4 SUPPL., 01.04.2007.

Research output: Contribution to journalArticle

Materson, Barry J. / Variability in Response to Antihypertensive Drugs. In: American Journal of Medicine. 2007 ; Vol. 120, No. 4 SUPPL.
@article{93a4e1d3b0db42c197c4a3f898884065,
title = "Variability in Response to Antihypertensive Drugs",
abstract = "Heterogeneity of treatment effects (HTE) is a measure of the variations in individual treatment response to the same agent across a population. Hypertension affords an appropriate model for investigators of HTE. Use of blood pressure measurement guidelines and consistent techniques help to reduce the potential variability associated with clinician measurements. Patient characteristics such as age and race/ethnicity can affect blood pressure, including patient response and adverse events observed with antihypertensive medication. Through pharmacogenetic advances, potential underlying causes for such variation are emerging. The growing number of clinical examples of mutations that affect antihypertensive response includes multiple polymorphisms within the components of the renin-angiotensin-aldosterone system. The most prominent examples of these polymorphisms exist in the genes coding for angiotensinogen, angiotensin-converting enzyme, and the angiotensin II type 1 receptor. An understanding of the components of blood pressure variability and sources of HTE in antihypertensive therapy is important for analyzing published reports on this topic. It is also helpful when designing treatment protocols for individual patients with hypertension and in assessing their response to therapy.",
keywords = "Antihypertensive drugs, Biologic characteristics, Drug resistance, Heterogeneity, Population characteristics, Populations at risk",
author = "Materson, {Barry J}",
year = "2007",
month = "4",
day = "1",
doi = "10.1016/j.amjmed.2007.02.003",
language = "English",
volume = "120",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Variability in Response to Antihypertensive Drugs

AU - Materson, Barry J

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Heterogeneity of treatment effects (HTE) is a measure of the variations in individual treatment response to the same agent across a population. Hypertension affords an appropriate model for investigators of HTE. Use of blood pressure measurement guidelines and consistent techniques help to reduce the potential variability associated with clinician measurements. Patient characteristics such as age and race/ethnicity can affect blood pressure, including patient response and adverse events observed with antihypertensive medication. Through pharmacogenetic advances, potential underlying causes for such variation are emerging. The growing number of clinical examples of mutations that affect antihypertensive response includes multiple polymorphisms within the components of the renin-angiotensin-aldosterone system. The most prominent examples of these polymorphisms exist in the genes coding for angiotensinogen, angiotensin-converting enzyme, and the angiotensin II type 1 receptor. An understanding of the components of blood pressure variability and sources of HTE in antihypertensive therapy is important for analyzing published reports on this topic. It is also helpful when designing treatment protocols for individual patients with hypertension and in assessing their response to therapy.

AB - Heterogeneity of treatment effects (HTE) is a measure of the variations in individual treatment response to the same agent across a population. Hypertension affords an appropriate model for investigators of HTE. Use of blood pressure measurement guidelines and consistent techniques help to reduce the potential variability associated with clinician measurements. Patient characteristics such as age and race/ethnicity can affect blood pressure, including patient response and adverse events observed with antihypertensive medication. Through pharmacogenetic advances, potential underlying causes for such variation are emerging. The growing number of clinical examples of mutations that affect antihypertensive response includes multiple polymorphisms within the components of the renin-angiotensin-aldosterone system. The most prominent examples of these polymorphisms exist in the genes coding for angiotensinogen, angiotensin-converting enzyme, and the angiotensin II type 1 receptor. An understanding of the components of blood pressure variability and sources of HTE in antihypertensive therapy is important for analyzing published reports on this topic. It is also helpful when designing treatment protocols for individual patients with hypertension and in assessing their response to therapy.

KW - Antihypertensive drugs

KW - Biologic characteristics

KW - Drug resistance

KW - Heterogeneity

KW - Population characteristics

KW - Populations at risk

UR - http://www.scopus.com/inward/record.url?scp=33947623101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947623101&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2007.02.003

DO - 10.1016/j.amjmed.2007.02.003

M3 - Article

C2 - 17403377

AN - SCOPUS:33947623101

VL - 120

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 4 SUPPL.

ER -